A very timely article (released on the 13th of December) highlighting the role of FTO in multiple myeloma progression (1). Of note, FTO inhibition (MA2: IC50 = 7uM) worked synergistically with the proteasome inhibitor, bortezomib, to inhibit bone tumor formation and extramedullary spread in NCG mice. This work compliments the in vitro research completed by RAC last week which demonstrated Zantrene was able to synergise with carfilzomib, a proteasome inhibitor, in cancer cells as well as provide cardioprotection to cardiomyocytes (2). The difference between the two studies is the recent cell paper has used an in vivo model, which may provide some confidence to holders that RAC's work will translate from a cell model to an animal.
I wonder how long it will take Amgen to partner with RAC? My guess is this will happen before the start of the new financial year.
Also, there are now 100 papers that have linked FTO upregulation to the progression of 28 different cancer types.
1. https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(21)00648-1
2. https://hotcopper.com.au/threads/ann-expanded-heart-protection-discovery-for-zantrene.6473741/
A very timely article (released on the 13th of December)...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.030(2.01%) |
Mkt cap ! $254.2M | |||
| Open | High | Low | Value | Volume |
| $1.51 | $1.53 | $1.48 | $141.7K | 94.55K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 427 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 2999 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.51 |
Change
0.030 ( 0.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.52 | $1.53 | $1.48 | 13236 | ||
| Last updated 15.53pm 21/05/2024 ? | |||||
| RAC (ASX) Chart |